BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.
Breast cancer metastasis suppressor gene-1 (BRMS1) mRNA and protein expression are significantly decreased in non-small cell lung cancer (NSCLC) and this is a poor prognostic indicator. Given that the BRMS1 promoter region contains a promoter-associated CpG island (CGI) that encompasses the transcriptional start site, we hypothesized that decreased BRMS1 mRNA and protein levels in NSCLC was secondary to increased BRMS1 promoter methylation. Methylation-specific PCR (MSP) of the two known CGIs (-3477 to - 2214 and - 531 to + 608) in the BRMS1 genome was performed in NSCLC cells. This demonstrated a robust increase in methylation of the promoter-associated CGI (-531 to + 608) but not of the upstream CGI (-3477 to - 2214). To experimentally verify that methylation contributes to BRMS1 transcriptional repression, we cloned the BRMS1 promoter region, including the promoter-associated CGI, into a luciferase reporter gene and found that BRMS1 promoter activity was dramatically inhibited under methylated conditions. We then assessed the BRMS1 methylation profile with MSP and bisulphite-sequencing PCR in human NSCLC adenocarcinoma (n = 20) and squamous cell carcinoma (n = 20) relative to adjacent non-cancerous bronchial epithelium. There was a significant increase in BRMS1 promoter methylation in all NSCLC specimens relative to non-cancerous tissues, with the most dramatic difference in squamous cell cancer histology. Subsequent immunostaining demonstrated that nuclear BRMS1 expression is reduced in lung cancer specimens compared to normal bronchial epithelium. The association between BRMS1 promoter methylation and specific clinical and histopathological variables was examined using a general linear model. Pathological tumour stage was associated with increased BRMS1 methylation in squamous cell cancers. These observations demonstrate that methylation of the promoter-associated CGI in BRMS1 results in its transcriptional repression, and highlight the potential clinical relevance of this methylation event with respect to NSCLC tumour histology and pathological stage.
Nagji
Alykhan S
AS
Department of Surgery, University of Virginia, Charlottesville, VA, USA.
Liu
Yuan
Y
Stelow
Edward B
EB
Stukenborg
George J
GJ
Jones
David R
DR
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D018899:CpG Islands / Q000235:genetics / Q000502:physiology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008745:Methylation; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D012097:Repressor Proteins; D014158:Transcription, Genetic
C410024:BRMS1 protein, human; D009363:Neoplasm Proteins; D012097:Repressor Proteins
Clin Cancer Res. 2006 Nov 1;12(21):6410-4
17085653
J Biol Chem. 2006 Jul 14;281(28):19700-8
16702213
J Natl Cancer Inst. 1997 May 7;89(9):624-9
9150186
Exp Cell Res. 2002 Feb 15;273(2):229-39
11822878
Clin Exp Metastasis. 2000;18(8):683-93
11827072
Cancer Res. 2005 May 1;65(9):3586-95
15867352
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):228-33
17190809
Cancer Res. 2001 Mar 1;61(5):1765-7
11280719
Mol Cancer. 2007 Jan 16;6:6
17227585
N Engl J Med. 2008 Mar 13;358(11):1118-28
18337602
Nat Genet. 2006 Dec;38(12):1378-85
17072317
Oncogene. 2002 Aug 12;21(35):5450-61
12154407
Cell Growth Differ. 1993 Oct;4(10):799-809
8274449
EMBO J. 1992 Jan;11(1):327-33
1310933
Genomics. 1992 Aug;13(4):1095-107
1505946
Nat Rev Genet. 2002 Jun;3(6):415-28
12042769
Cancer Lett. 2009 Apr 18;276(2):196-203
19111386
Cancer Res. 2000 Jun 1;60(11):2764-9
10850410
Oncogene. 1991 Oct;6(10):1859-68
1717924
Trends Genet. 2000 Apr;16(4):168-74
10729832
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Tumour Biol. 2009;30(3):148-59
19609101
Mol Cell Biol. 2006 Dec;26(23):8683-96
17000776
J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8
15592684
Cancer Res. 2001 May 1;61(9):3581-5
11325823
FEBS Lett. 2009 Jun 5;583(11):1713-20
19376112
Cancer Sci. 2003 Jul;94(7):589-92
12841866
Nat Med. 1995 Jul;1(7):686-92
7585152
Trends Genet. 2008 Oct;24(10):481-4
18786740
Cancer. 2006 Apr 15;106(8):1751-8
16534787
Clin Genet. 2005 Aug;68(2):128-36
15996209
J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30
11058615
J Thorac Oncol. 2007 Apr;2(4):327-43
17409807
Mol Cell Biol. 1994 Aug;14(8):5487-94
7518564
Clin Exp Metastasis. 2008;25(7):753-63
18566899
Cancer Res. 2005 Feb 1;65(3):713-7
15705865
Cancer Res. 2001 Jan 1;61(1):249-55
11196170